Walder Wyss advises Pfizer on its investment in Anokion
As we have informed here last 10 November 2022, the clinical-stage biotechnology company Anokion has closed an USD 35 million equity investment from Pfizer through the Pfizer Breakthrough Growth Initiative. The Biotech company is focus on the treating autoimmune disease by restoring normal immune tolerance.
Walder Wyss has also advised on the deal acting as Swiss legal advisor to Pfizer. The team included Urs Schenker (counsel, pictured left), Samuel Lieberherr (managing associate, pictured center) and Timon Nydegger (senior associate, pictured right), all corporate/m&a.
